Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23485120 | 1.00 | L3MBTL1 (0.33) | L3MBTL1DPP4DPP8DPP9PIK3CD | |
| SCHEMBL2707422 | 1.00 | L3MBTL1 (0.33) | L3MBTL1DPP4DPP8DPP9PIK3CD | |
| SCHEMBL23488614 | 0.79 | L3MBTL1 (0.43) | L3MBTL1PIK3CD | |
| SCHEMBL9980259 | 0.76 | L3MBTL1 (0.38) | L3MBTL1DPP4DPP8DPP9MAPK1 | |
| SCHEMBL2757452 | 0.76 | MAPK1 (0.35) | DPP4DPP8DPP9PIK3CDMAPK1 | |
| SCHEMBL10052288 | 0.74 | — | — | |
| SCHEMBL2705993 | 0.74 | — | — | |
| SCHEMBL14558062 | 0.72 | MMP2 (0.36) | L3MBTL1DPP4DPP8DPP9 | |
| SCHEMBL21145968 | 0.71 | PIK3CD (0.33) | DPP4DPP8DPP9PIK3CD | |
| SCHEMBL15462354 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-11357828-B2 | Releasable GLP-1 conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2022-06-14 | — | — | US | disclosed |
| US-20220118055-A1 | RELEASABLE GLP-1 CONJUGATES | FISH & RICHARDSON PC | 2022-04-21 | — | — | US | disclosed |
| US-20210170045-A1 | RELEASABLE ANTIBODY CONJUGATES | FISH & RICHARDSON PC | 2021-06-10 | — | — | US | disclosed |
| US-8623814-B2 | Antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8178531-B2 | Antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110218175-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-20110206637-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218175-A1 | ANTIVIRAL AGENTS | EIF2AK2, HAVCR2, MAVS | L3MBTL1 3897/4885DPP4 314/4885DPP8 534/4885 |
| US-20210170045-A1 | RELEASABLE ANTIBODY CONJUGATES | BCR, CD47, RNASE1 | L3MBTL1 956/4885DPP4 1294/4885DPP8 1065/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | L3MBTL1 3548/4885DPP4 828/4885DPP8 955/4885 |
| US-20110206637-A1 | ANTIVIRAL AGENTS | EIF2AK2, ZC3HAV1, MAVS | L3MBTL1 4169/4885DPP4 126/4885DPP8 273/4885 |
| US-11357828-B2 | Releasable GLP-1 conjugates | GLP1R, GIPR, IAPP | L3MBTL1 1957/4885DPP4 11/4885DPP8 21/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | L3MBTL1 3548/4885DPP4 828/4885DPP8 955/4885 |
| US-20220118055-A1 | RELEASABLE GLP-1 CONJUGATES | GLP1R, GIPR, IAPP | L3MBTL1 1957/4885DPP4 11/4885DPP8 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.